Allergic asthma is a major and increasingly prevalent public-health problem. Acute asthma exacerbations are a serious unmet medical need. Respiratory virus infections (mostly caused by rhinovirus (RV)) are strongly associated with asthma exacerbations [1] [2] [3] , and synergistic interactions between allergen sensitization and exposure and virus infections increase the risk of exacerbation 4, 5 , although the mechanisms involved are poorly understood. Key aspects of RV-induced exacerbations are orchestrated by type-2 immune cells, in particular, adaptive type-2 helper T (T H 2) cells 3, [6] [7] [8] [9] . Given that viral infections induce immune responses with a predominant type-1 profile 10,11 , additional factors must participate in such type-2-immune-mediated exacerbation 3 .
RESULTS

RV-induced dsDNA is related to asthma exacerbation severity
To determine whether host dsDNA is released during RV-induced asthma exacerbations and to assess the relationship between RV infection, host dsDNA and type-2 immune responses, we analyzed nasal-lavage samples collected after RV-16 inoculation from 23 (who had lavage available) of 28 individuals with mild to moderate atopic asthma and 11 healthy control individuals who had previously participated in a study investigating asthma exacerbation pathogenesis 7, 9 ( Fig. 1a and Supplementary Table 1 ). Because rhinoviruses are RNA viruses with no dsDNA intermediates, dsDNA detected in the airways after RV infection is most likely derived from the host. Nasal dsDNA concentrations in the upper airways were increased on day 2 postinoculation (p.i.) with RV, as compared to baseline, both in healthy individuals and those with asthma, but to a higher extent in the latter group (Fig. 1b) . On days 3, 4 and 7, dsDNA concentrations were a r t i c l e s 6 8 2 VOLUME 23 | NUMBER 6 | JUNE 2017 nature medicine induced as compared to baseline in individuals with asthma but not in healthy volunteers, and were greater in individuals with asthma ( Fig. 1b) . After infection with RV, peak concentrations of dsDNA (i.e., the maximal concentrations of dsDNA detected during the infection for each individual) were increased in both groups of volunteers when compared to baseline, but peak concentrations of dsDNA were higher in individuals with asthma as compared to healthy volunteers (Fig. 1c) . No differences were found between individuals with asthma treated with inhaled corticosteroids (ICS) or without ICS treatment ( Supplementary Fig. 1a-c) .
As reported in the original study 9 , the type-2 cytokines interleukin (IL)-5 and IL-13 were induced by RV infection in the noses of the 23 individuals with asthma included herein, and peak nasal concentrations were higher during infection in individuals with asthma than in healthy volunteers (data not shown). One exception was IL-4, which achieved statistical significance between baseline and the peak and between control and asthma groups in the original study 9 , but not in the current subgroups (Supplementary Fig. 1d ). Nonetheless, peak concentrations of all three type-2 cytokines were correlated with those of nasal dsDNA during infection (Fig. 1d) . Concentrations of the type-1 cytokine interferon (IFN)-γ, which were increased in both groups after RV infection but were not different between individuals with asthma and healthy volunteers (data not shown), were also correlated with dsDNA release (Fig. 1d) . (b,c) Asterisks (*) compare differences within groups; circles (°) compare differences between individuals with asthma and healthy volunteers at the indicated time points (b) or at the peak (c). The statistical significances of the differences between the baseline and the various time points or the peak levels, and between the cohorts at the various time points were determined using contrasts between least square means estimated in the mixed model (described in Online Methods). (d-g) The correlation analysis used was nonparametric (Spearman's correlation) performed on healthy volunteers and individuals with asthma pooled into a single group. Error bars indicate s.e.m. n.s., not significant; * /°P < 0.05; ** /°°P < 0.01; *** /°°°P < 0.001. a r t i c l e s nature medicine VOLUME 23 | NUMBER 6 | JUNE 2017 6 8 3
As previously reported 9 , nasal viral loads on day 3 were higher in the individuals with asthma included herein, as compared to healthy volunteers (data not shown), and were correlated with dsDNA concentrations (Fig. 1e) . The 23 individuals with asthma included herein also displayed greater upper and lower respiratory symptom scores (RSS) than did healthy individuals after inoculation with RV 9 (data not shown). Nasal concentrations of host dsDNA were positively correlated not only with cold-symptom severity (total upper RSS), but importantly, also with asthma exacerbation severity (total lower RSS) (Fig. 1f) , and the associated lower-airway type-2 (bronchial mucosal-lining fluid concentrations of IL-5 and IL-13 (ref. 9)) immune response (Fig. 1g) .
These results show that RV infection in individuals with asthma induces dsDNA release, which correlates with type-2 immunemediated asthma exacerbation severity.
RV induces dsDNA in a mouse model of asthma exacerbation To further investigate the relationships between RV-mediated release of host dsDNA and asthma exacerbation, we employed a clinically relevant mouse model ( Fig. 2a) able to recapitulate key aspects of RVinduced asthma exacerbation in humans 9 . House dust mite (HDM)-sensitized BALB/c mice that were challenged with HDM (hereafter referred to as 'allergic' mice) exhibited signs of allergic airway inflammation when compared to phosphate-buffered saline (PBS)-sensitized HDM-challenged controls, including higher numbers of total cells, eosinophils and lymphocytes in the bronchoalveolar lavage fluid (BALF), and higher serum concentrations of IgE and HDM-specific IgG 2a and IgG 1 (Fig. 2b,c and Supplementary Fig. 2a-d) . Allergic mice inoculated with RV-1b displayed exacerbated features of asthma when compared to allergic mice inoculated with ultraviolet-inactivated RV-1b (UV) and RV-inoculated, nonallergic mice, including increased numbers of total cells; increased numbers and percentages of eosinophils and lymphocytes in the BALF; higher serum concentrations of IgE; greater concentrations of BALF Muc5ac protein; enhanced airway-inflammatory cell infiltration and mucus production; and airway hyper-reactivity (Fig. 2b-g and Supplementary Fig. 2a-g ). Viral load was similar between RV-inoculated allergic and nonallergic animals ( Supplementary Fig. 2h) .
The quantification of lung T H 2 lymphocytes (defined here as singlet, live SSC low CD3 + CD4 + ICOS + ST2 + cells 21 ; Fig. 2h ) revealed higher numbers and percentages of these immune cells in the lungs of RV-infected allergic mice than in uninfected allergic and infected nonallergic mice (Fig. 2i,j and Supplementary Fig. 3a,b) . In addition, lung and mediastinal lymph node (MLN) cells isolated from RV-infected allergic mice produced more T H 2 cytokines than cells isolated from uninfected allergic and infected nonallergic mice upon HDM restimulation ex vivo (Fig. 2k,l and Supplementary Fig. 3c,d ). None of the T H 2 cytokines were detectable in unstimulated cells (data not shown). These results confirm that RV-induced exacerbation of allergic airway inflammation is associated with a robust type-2 immune response in a clinically relevant context.
We next sought to investigate whether dsDNA was released following RV inoculation in our model. In naive mice, RV induced an early burst of dsDNA release in the airways starting at 24 h, peaking at day 2 and returning to baseline 4 d p.i. (Fig. 2m) . In the allergy setting, HDM challenge in combination with UV-treated virus inoculation induced low levels of dsDNA. As in naive mice, dsDNA was robustly increased in RV-infected nonallergic mice. Further induction was observed in RV-infected allergic animals as compared to both uninfected allergic and infected nonallergic mice (Fig. 2n) .
These results recapitulate our observations in humans (Fig. 1b,c) that RV infection is able to trigger dsDNA release, and that this is amplified in the airways of allergic subjects.
DNase protects against RV-induced exacerbation
To investigate whether dsDNA could drive type-2-immune-mediated asthma exacerbation, we treated mice with DNase (Fig. 3a) , abolishing dsDNA accumulation in the airways of mice inoculated with RV ( Fig. 3b and Supplementary Fig. 4a,b) .
DNase-treated RV-infected allergic mice had reduced features of allergic asthma exacerbation as compared to vehicle-treated counterparts, with lower numbers of total cells; lower numbers and percentages of eosinophils and lymphocytes in the BALF; reduced concentrations of serum IgE; reduced concentrations of BALF Muc5ac protein and airway inflammatory cell infiltration; less mucus production; and reduced airway hyper-reactivity (Fig. 3c-h and Supplementary Fig. 4c-f) . DNase treatment did not affect BALF neutrophil numbers and viral replication (Supplementary Fig. 4d,g ), which suggests that the reduction of exacerbated disease was not due to a difference in viral loads. Serum concentrations of HDMspecific IgG 2a and IgG 1 remained unchanged upon DNase treatment (Supplementary Fig. 4h ).
Assessing specifically type-2 immune responses, DNase treatment also reduced numbers and percentages of lung T H 2 lymphocytes ( Fig. 3i and Supplementary Fig. 5a,b ), as well as T H 2 cytokine production, following HDM restimulation of lung and MLN cells ex vivo (Fig. 3j,k and Supplementary Fig. 5c,d) .
Thus, DNase treatment substantially reduced type-2 immune responses and RV-induced exacerbation of allergic airway inflammation, in keeping with the idea that extracellular DNA contributes to the boosting of type-2 immune responses and exacerbation of asthma by RV.
dsDNA is sufficient to boost type-2 immune responses Next, we investigated whether exogenous dsDNA, when injected alone, could recapitulate features of virus-driven exacerbation of type-2 immune responses and asthma pathology (Fig. 4a) . The administration of dsDNA from mouse splenocytes recapitulated many, but not all, of the immune and pathological features seen after RV infection. When compared to vehicle-treated allergic mice, dsDNA-treated allergic mice exhibited greater numbers of total cells, numbers and percentages of eosinophils and lymphocytes in the BALF, concentrations of serum IgE, airway inflammatory cell infiltration and lung and MLN-associated type-2 immune responses (Fig. 4b,c ,e,h-j, Supplementary Fig. 6a-d and Supplementary Fig. 7a-d) . However, dsDNA-treated allergic mice did not exhibit greater mucus production or enhanced airway hyperactivity when compared to vehicle-treated allergic mice (Fig. 4d ,f,g and Supplementary Fig. 6e ). Similarly to RV infection, dsDNA did not increase serum concentrations of HDM-specific IgG 2a or IgG 1 above concentrations seen in allergic mice ( Supplementary Fig. 6f ). In nonallergic mice, dsDNA treatment did not interfere with any aspect of lung inflammation assessed in this model ( Supplementary Fig. 6 and Supplementary Fig. 7) .
Thus, host dsDNA release, as observed after RV infection, is sufficient to exacerbate many features of type-2-mediated allergic inflammation.
DNase inhibits monocyte-derived dendritic cell recruitment During T H 2 sensitization, host dsDNA acts preferentially on dendritic cells (DCs) to boost type-2 immune responses 19, 20 , and monocytederived DCs (mo-DCs) are recruited to the lung and, subsequently, to the MLN upon allergen challenge to maintain T H 2 cell-mediated a r t i c l e s 
Assessment of lung T H 2 lymphocytes
Assessment of HDM-specific T H 2 cytokine production ex vivo immunity to HDM 22 . We thus reasoned that DNase may suppress type-2-immune-mediated exacerbations by inhibiting mo-DC recruitment in our model. Numbers of mo-DCs (defined here as singlet, live CD11c + MHC-II high CD103 − CD11b + CD64 + cells 22 ) and also CD11b + conventional DCs (cDC2, defined here as singlet, live CD11c + MHC-II high CD103 − CD11b + CD64 − MAR-1 − cells 22 ), the DC subset responsible for priming T H 2 responses to HDM 23, 24 , were evaluated on day 3 p.i. (Fig. 5a) . As expected in allergic mice 22 , numbers of mo-DCs recruited to the lung were higher than those in PBS-sensitized controls (Fig. 5b,c) . However, there was no recruitment of mo-DCs to the MLNs (Fig. 5e,f) . After RV infection alone, numbers of mo-DCs were higher in the lungs and MLNs of RV-inoculated mice than in those of UV-inoculated controls, and numbers were further increased in the lungs and MLNs of infected allergic mice (Fig. 5c,f) . Numbers of cDC2 were also higher in the lungs of allergic mice and in RV-infected mice than in UV-inoculated nonallergic control mice, but unlike mo-DCs, cDC2 numbers were not higher in RV-infected allergic mice than in UV-inoculated allergic controls (Fig. 5d) . In the MLNs, numbers of cDC2 were also increased in RV-inoculated as compared to UV-inoculated allergic mice (Fig. 5g) .
We then investigated whether mo-DC recruitment to the lung and MLNs was affected by DNase treatment, and found that DNasetreated RV-infected allergic mice had lower numbers of mo-DCs in the lungs and MLNs than did their vehicle-treated counterparts (Fig. 5c,f) . Conversely, DNase treatment of RV-infected allergic mice did not reduce numbers of cDC2 in the lungs or MLNs when compared to their vehicle-treated counterparts (Fig. 5d,g ).
During respiratory syncytial virus (RSV) infection, mo-DC recruitment is driven by the chemokines CCL2, CCL7 and CCL12 (ref. 25 ). 1 d p.i., a r t i c l e s BALF concentrations of CCL2, CCL7 and CCL12 were increased in RVinfected allergic mice as compared to UV-inoculated controls (Fig. 5h-j) . Moreover, the concentrations of CCL7 and CCL12 were higher in RVinoculated allergic mice than in RV-inoculated nonallergic mice (Fig. 5i,j) . DNase treatment substantially decreased concentrations of CCL2 and CCL7, but not CCL12, in DNase-treated RV-infected allergic and nonallergic mice as compared to their vehicle-treated counterparts. Taken together, our results are concordant with the hypothesis that RV-induced extracellular dsDNA, by promoting CCL2 and CCL7 secretion and boosting mo-DC recruitment, contributes to RV-induced exacerbation of allergic airway inflammation.
RV-induced NETs mediate asthma exacerbation pathogenesis
We next investigated mechanisms underlying dsDNA release during RV-induced asthma exacerbations. Virus-induced asthma exacerbations are associated with neutrophil recruitment to the airways 12, 13 , and viruses are able to prime neutrophils to extrude NETs 26 , mainly composed of dsDNA. We therefore postulated that RV infection could induce NETs, which would thus provide a source of dsDNA to contribute to the exacerbation of allergic asthma.
In human nasal lavages, the NET-associated protein NE 16,27 was induced by RV infection only in individuals with asthma, and there was a nonsignificant trend toward increased NE during infection in individuals with asthma as compared to healthy volunteers (Fig. 6a) . In addition, nasal concentrations of NE were positively correlated with those of dsDNA at day 4 p.i. (Fig. 6b) . Thus, NETs induced by RV infection are a likely source of dsDNA in RV-infected human airways. In our mouse model, NE concentrations were also increased in the BALF of RV-inoculated mice at day 1 p.i., were greater in RV-infected allergic mice than in both uninfected allergic and infected nonallergic mice (Fig. 6c ) and were correlated with dsDNA concentrations (Fig. 6d) .
To assess the dependency of dsDNA release on neutrophil recruitment to the airways of RV-infected allergic mice, neutrophils were depleted by treating mice intraperitoneally (i.p.) with anti-Ly6G-neutralizing antibodies (α-Ly6G) before RV inoculation (Fig. 6e) . α-Ly6G treatment blocked RV-induced neutrophil recruitment to the airways (Fig. 6f) , and decreased BALF dsDNA to concentrations observed in UV-inoculated allergic mice (Fig. 6g) .
To unambiguously test whether RV can induce NETs in the lungs of mice, we performed identification and relative quantification of NET formation in our model of RV-induced asthma exacerbation. NETs were identified by immunofluorescence as areas staining triple positive for DNA, citrullinated histone H3 (Cit-H3) and MPO (a NET-associated protein 16 ), and these regions were semi-quantified by western blots of Cit-H3 in the lungs of mice 28 . NETs were abundantly present in the lungs of RV-infected mice at day 2 p.i., regardless of their allergic status (Fig. 6h,i, Supplementary Fig. 8 and Supplementary Fig. 9a-f) . NETs and Cit-H3 were virtually absent in the lungs of UV-inoculated allergic and nonallergic mice. Blocking neutrophil recruitment with α-Ly6G abolished NET and Cit-H3 protein detection in the lungs without affecting eosinophil numbers (Fig. 6h,i and Supplementary Fig. 9 ), demonstrating that neutrophils, but not eosinophils, represented the source of extracellular traps and dsDNA. To corroborate this further, we assessed neutrophil recruitment and dsDNA concentrations in eosinophil-deficient ∆dblGATA BALB/c mice, in which targeted deletion of the double palindromic GATA-1-binding site in the Gata1 promoter results in eosinophil deficiency 29 (Supplementary Fig. 10a ). The numbers of neutrophils and dsDNA were not affected by eosinophil deficiency ( Supplementary  Fig. 10b,c) . These data confirmed that dsDNA release in RV-infected allergic mice was dependent on neutrophil-derived, but not eosinophilderived, extracellular traps.
Finally, to formally assess the contribution of NETs to RV-induced asthma exacerbation and avoid nonspecific effects of DNase, we used a specific inhibitor of NETosis (GW311616A; a neutrophil-elastase inhibitor, NEi 16, 27 ) in our mouse model ( Fig. 6j and Supplementary  Fig. 11a) . We confirmed that NEi reduced RV-induced NETs in the airways of infected mice (Supplementary Fig. 11b-d) without affecting BALF neutrophil numbers and viral load (Fig. 6k,l) . NEi-treated RV-infected allergic mice displayed a reduction in several features of type-2-mediated exacerbation of allergic airway inflammation when compared to vehicle-treated counterparts, including fewer total BALF cells, eosinophils and lymphocytes (Fig. 6l) , reduced airway hyperreactivity (Fig. 6m) , lower numbers and percentages of lung T H 2 cells and lower release of T H 2 cytokines from HDM-restimulated MLN cells (Fig. 6n,o) . We conclude that NETs are induced by RV in vivo, and that targeting NETosis recapitulates the effects of DNase treatment (Fig. 3) and allows for the protection of mice from RV-induced exacerbation of allergic airway inflammation.
DISCUSSION
The nature of the signals that amplify T H 2 responses during virusinduced asthma exacerbation remains a crucial question in asthma research. Building on previous studies reporting that dsDNA released from dying host cells is responsible for developing type-2 immune responses following alum-mediated sensitization 19, 20 , we show here that host-derived dsDNA released during RV infection is amplified in individuals with asthma undergoing RV-induced asthma exacerbations, and that dsDNA levels are strongly related to both exacerbation symptom severity and RV-induced type-2 cytokine release. Similar increases in airway levels of dsDNA are also found in RV-infected mice.
Here we developed a clinically relevant mouse model of RV-induced exacerbation of allergic airway inflammation that recapitulates many features of RV-induced asthma exacerbation in humans. Indeed, although RV-1b does not naturally infect mice and its capability to replicate is limited to 1 or 2 d 6 , features of allergic asthma exacerbations in the mouse model are of substantial duration and are completely dependent on virus replication, as in humans. Moreover, the timing of dsDNA and exacerbation responses is similar in mice and humans, with a peak of dsDNA release on day 2, and asthma exacerbation is detectable at day 3 or 4 (as quantified by the respiratory scores in humans 9 and airway hyper-reactivity and allergic airway inflammation in mice).
Exogenous DNase administration abolished all relevant exacerbation outcomes in this model, revealing a crucial functional role of dsDNA or dsDNA-containing structures in RV-induced exacerbation of type-2-mediated allergic airway inflammation.
Two major sources of extracellular host DNA in tissues are NETs and necrotic cells. When injected in the absence of virus infection, dsDNA from splenocytes recapitulated many, but not all, of the exacerbating effects of RV on asthma-related outcomes in mice, which suggests that more complex structures containing dsDNA, rather than dsDNA alone, were responsible for the full aggravating effects. This assumption was concordant with the fact that the commercially available DNase that we used degrades not only dsDNA but also DNA-associated proteins 19, [30] [31] [32] [33] . We therefore postulated that NETs, which contain both dsDNA and proteins, were the main source of airway dsDNA elicited by RV infection. This hypothesis is supported by several observations. First, RV-1b robustly induced NETs in RV-infected animals. Second, NET inhibition in RV-infected mice had the same beneficial effects as DNase on the characteristic features of asthma. Third, Ly6G-blocking antibody almost completely abolished neutrophil recruitment and NET formation and decreased levels of dsDNA to levels observed in noninfected allergic mice. Fourth, the use of eosinophil-deficient ∆dblGATA mice rules out a potential contribution of eosinophils as a source of extracellular traps and dsDNA. Finally, experimental RV-16 infection in humans induces NE release, which correlated with the nasal levels of dsDNA.
However, there is significant dsDNA release in noninfected HDMexposed mice in the absence of NETs. We speculate that, in this case, HDM induces dsDNA release by other mechanisms, an action likely related to HDM-induced tissue damage 34 , and that this dsDNA is derived from necrotic airway-resident cells, rather than NETs.
Several publications have suggested that host dsDNA exerts its effects mainly on innate immune cells through the type-1-interferoninducing STING-TBK1-IRF3-dependent signaling pathway 19, 20, [35] [36] [37] [38] . In this study, in agreement with previous ones 19, 20 , we propose that NET-derived dsDNA acts as an adjuvant to promote the recruitment of pro-T H 2 DCs to the lung and to the MLNs. More specifically, our data support the idea that RV infection, by inducing NETs, is able to boost mo-DC recruitment during the allergen challenge, which has been shown to maintain specifically T H 2-cell-mediated immunity against HDM 22 . Another report suggested that mo-DC recruitment was driven after RSV infection to preferentially induce T H 1 immune responses 25 , which suggests that the functional specialization of mo-DCs during RV infection most probably originates from the T H 2 microenvironment. However, in nonsensitized mice, the release of dsDNA during RV infection increases mo-DC recruitment without promoting type-2 immune responses, which suggests a need to provide two separate signals-one from the T H 2 microenvironment and the other from the virus-to enable mo-DCs to drive the exacerbation of T H 2-mediated adaptive immune responses.
In addition to acting on mo-DCs, there are other ways by which dsDNA could contribute to the exacerbation of allergic airway inflammation. An earlier study has demonstrated that host dsDNA released from dying cells and complexed with antimicrobial peptide is able to directly stimulate CD4 + T cells to induce T H 2 cell differentiation and activation 18 . Several others have reported that NETs and antimicrobial peptides are both released during respiratory viral infection 39, 40 , which suggests that, in addition to the role of mo-DCs, a complex of dsDNA and antimicrobial peptides released during the NETosis process could interact with CD4 + T cells and exacerbate type-2 immune responses.
Given that dsDNA alone only partially recapitulates the exacerbating effects of RV infection, it is reasonable to postulate that other NET-associated molecules may contribute to virus-induced exacerbation of allergic airway inflammation. Among these molecules, the antimicrobial peptide LL37 has been reported to facilitate the transport of self-dsDNA into antigen-presenting cells 35, 41 , making it a possible partner in helping dsDNA to boost type-2 responses. In addition, other studies have shown that NE can contribute to airway hyper-responsiveness and airway inflammation in rodent models 42, 43 , and we show that the inhibition of NE can attenuate RV-induced airway hyper-reactivity in our model. These data, together with the fact that dsDNA alone, as opposed to RV-1b inoculation, did not increase airway hyper-reactivity, support the hypothesis that NET-derived NE may contribute to airway hyper-reactivity during exacerbation. The other NET-associated proteins instead seem to have inhibitory functions on type-2 immunity. Indeed, cathepsin G stimulated type-1 IFN production by plasmacytoid DCs, which in turn stimulated antiviral responses and autoimmunity but dampened type-2 immune responses 44, 45 . Moreover, NE has also been reported to attenuate DC maturation and function, resulting in a reduced allostimulatory ability or the inactivation of regulatory T cells [46] [47] [48] . Further experiments will be required to determine the respective roles of these NET-associated-proteins.
NETs, by releasing dsDNA and antimicrobial peptides, are beneficial defense structures that can help the host to fight against a r t i c l e s infections 26, 49, 50 . However, several studies have revealed that NETs could exert adverse effects characterized by massive influx of neutrophils into the lung when their regulation is altered 40, 49, 51 . In line with these studies, our data confirm that massive neutrophil recruitment and excessive NET deposits associated with substantial dsDNA release in the airway of allergic mice after RV infection promotes the exacerbation of type-2 immune responses. Given that other major causes of asthma exacerbation (for example, bacterial infection and cigarette smoke 40, 52, 53 ) are related to neutrophil recruitment and NETosis, it would be interesting to investigate the impact of NETs and associated dsDNA on the exacerbation of type-2 immune responses in these conditions, as well.
A remaining question is how RV infection drives NETosis. Because neutrophils are not a target for RV replication 54 , it is plausible that the virus itself is not able to promote NETosis, and that secondary signals are needed during RV infection to drive this process in vivo. Investigation of the signal(s) induced by the virus to promote NETosis would be an intriguing perspective for future research. Given that dsDNA starts to be released 24 h after RV inoculation in mice, and that NETs are clearly present at 48 h, it is plausible that the secondary signals activating NETosis are released from RV-infected respiratory epithelial cells, the primary site of RV replication 54 .
In conclusion, our findings identify a novel, important role for NETs and NET-associated dsDNA in virus-induced asthma exacerbation. Our data also suggest that controlling the release of NETs (for example, by using inhibitors of NETosis) or speeding up their clearance (for example, with DNase) could be a potential therapeutic option for the treatment of virus-induced exacerbation of type-2 immune responses.
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